TheCitizen - It's all about you
  • Home
  • Headlines
  • Latest News
  • Governance
  • Business
  • Financial Crimes
  • Opinion
  • Editorials
No Result
View All Result
TheCitizen - It's all about you
  • Home
  • Headlines
  • Latest News
  • Governance
  • Business
  • Financial Crimes
  • Opinion
  • Editorials
No Result
View All Result
TheCitizen - It's all about you
No Result
View All Result

Pfizer, BioNTech dose first participants in U.S in COVID-19 vaccine trial

The Editor by The Editor
May 6 2020
in Business
A A
0
Pfizer readies COVID-19 vaccine for September launch

Pfizer and BioNTech announced on Wednesday, May 6, 2020 that the first participants have been dosed in the U.S in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19.

The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week.

The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study.

The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S will enroll up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age).

The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age.

Older adults will only be immunized with a given dose level of a vaccine candidate once testing of that candidate and dose level in younger adults has provided initial evidence of safety and immunogenicity. Sites currently dosing participants include NYU Grossman School of

Medicine and the University of Maryland School of Medicine, with the University of Rochester Medical Center/Rochester Regional Health and Cincinnati Children’s Hospital Medical Center to begin enrollment shortly.

“With our unique and robust clinical study program underway, starting in Europe and now the U.S., we look forward to advancing quickly and collaboratively with our partners at BioNTech and regulatory authorities to bring a safe and efficacious vaccine to the patients who need it most. The short, less than four-month timeframe in which we’ve been able to move from pre-clinical studies to human testing is extraordinary and further demonstrates our commitment to dedicating our best-in-class resources, from the lab to manufacturing and beyond, in the battle against COVID-19,” said Albert Bourla, Chairman and CEO, Pfizer.

Pfizer and BioNTech’s development program includes four vaccine candidates, each representing a different combination of mRNA format and target antigen.

The novel design of the trial allows for the evaluation of the various mRNA candidates simultaneously in order to identify the safest and potentially most efficacious candidate in a greater number of volunteers, in a manner that will facilitate the sharing of data with regulatory authorities in real time.

“It is encouraging that we have been able to leverage more than a decade of experience in developing our mRNA platforms to initiate a global clinical trial in multiple regions for our vaccine program in such a short period. We are optimistic that advancing multiple vaccine candidates into human trials will allow us to identify the safest, most effective vaccination options against COVID-19,” said CEO and Co-founder of BioNTech, Ugur Sahin.

During the clinical development stage, BioNTech will provide clinical supply of the vaccine from its GMP-certified mRNA manufacturing facilities in Europe.  In anticipation of a successful clinical development program, Pfizer and BioNTech are working to scale up production for global supply.

Pfizer plans to activate its extensive manufacturing network and invest at risk in an effort to produce an approved COVID-19 vaccine as quickly as possible for those most in need around the world.

The breadth of this program should allow production of millions of vaccine doses in 2020, increasing to hundreds of millions in 2021.

Pfizer-owned sites in three U.S. states (Massachusetts, Michigan and Missouri) and Puurs, Belgium have been identified as manufacturing centers for COVID-19 vaccine production, with more sites to be selected.

Through its existing mRNA production sites in Mainz and Idar-Oberstein, Germany, BioNTech plans to ramp up its production capacity to provide further capacities for a global supply of the potential vaccine.

BioNTech and Pfizer will work jointly to commercialize the vaccine worldwide upon regulatory approval (excluding China, where BioNTech has a collaboration with Fosun Pharma for BNT162 for both clinical development and commercialization).

Previous Post

COVID-19: Quickteller Paypoint to provide support for agents

Next Post

IMF disburses $3.4bn emergency loan to Nigeria

Related Posts

Shell commends oil industry reforms as key to unlocking more barrels
Business

Shell commends oil industry reforms as key to unlocking more barrels

November 12 2026
Stanbic IBTC unveils platform for direct naira-yuan payments
Business

Stanbic IBTC unveils platform for direct naira-yuan payments

November 12 2026
Banks get three-month deadline to stop forex-backed loans
Business

CBN introduces digital fiscal reporting for states, LGAs

November 12 2026
Dangote Cement begins Ivory Coast operations
Business

Dangote pulls plug on London listing of cement empire

November 10 2026
Air Peace flight returns to ramp after passenger threatens to burn down plane
Business

Air Peace flight returns to ramp after passenger threatens to burn down plane

November 10 2026
MAKEMS unveils signature jewellery showroom in Abuja
Business

MAKEMS unveils signature jewellery showroom in Abuja

November 9 2026
Next Post
The warnings on debt burden – Thisday

IMF disburses $3.4bn emergency loan to Nigeria

Oyo govt bans illegal fees collection in schools

Two COVID-19 patients missing in Oyo, says Makinde

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

FROM THE GRASSROOTS

Fasoranti: Family announces Dec 17 for funeral

Fasoranti: Family announces Dec 17 for funeral

by The Editor
October 23 2026
0

...

Ooni, Omisore mourn Afenifere leader Fasoranti

Ooni, Omisore mourn Afenifere leader Fasoranti

by The Editor
October 21 2026
0

...

Minister defends King’s College concession, cites infrastructure decay

Minister defends King’s College concession, cites infrastructure decay

by The Editor
September 16 2026
0

...

Lagos demolishes shanties after four die in community clash

Lagos demolishes shanties after four die in community clash

by The Editor
August 30 2026
0

...

APPOINTMENTS

Makinde swears in four Oyo permanent secretaries

Makinde swears in four Oyo permanent secretaries

by The Editor
November 10 2026
0

...

Enugu APC releases updated campaign council list

by The Editor
October 31 2026
0

...

Gov. Okpebholo elevates ex-BBNaija housemate to adviser

Gov. Okpebholo elevates ex-BBNaija housemate to adviser

by The Editor
October 22 2026
0

...

CJN swears in 68 new SANs

CJN swears in 68 new SANs

by The Editor
October 12 2026
0

...

ODDITIES

Man stabs neighbor to death over roasted meat

Man stabs neighbor to death over roasted meat

by The Editor
November 5 2026
0

US pastor marries second wife, says monogamy unbiblical

US pastor marries second wife, says monogamy unbiblical

by The Editor
October 26 2026
0

Indian man assaults truck drivers in Lagos

Indian man assaults truck drivers in Lagos

by The Editor
October 13 2026
0

GLOBAL NEWS

Canada flags Nigeria, 16 African countries as high-risk in new travel advisory

Canada to fast-track permanent residence for 200,000 foreigners in 2027

by The Editor
November 12 2026
0

...

Court overturns gay sex ban in Trinidad & Tobago

Court overturns gay sex ban in Trinidad & Tobago

by The Editor
November 11 2026
0

...

US warns citizens against travel to 23 countries

US warns citizens against travel to 23 countries

by The Editor
November 10 2026
0

...

Russia agrees to ban recruitment of Ghanaian nationals for Ukraine war

Russia agrees to ban recruitment of Ghanaian nationals for Ukraine war

by The Editor
November 2 2026
0

...

Britain shouldn’t apologise for slave trade; Africa profited, says Kemi Badenoch

Britain shouldn’t apologise for slave trade; Africa profited, says Kemi Badenoch

by The Editor
November 2 2026
0

...

State of the States

Katsina mob kills Customs officer for shooting passenger

Hisbah bans girls’ night hawking in Katsina

by The Editor
November 12 2026
0

...

Kano closes schools for Eid-el-Kabir

Kano governor unveils N50,000 grants for 5,200 women

by The Editor
November 10 2026
0

...

Delta SUBEB denies N13.4bn unspent funds claim

Delta SUBEB denies N13.4bn unspent funds claim

by The Editor
October 31 2026
0

...

Ogun State mulls relocation of communities over gas leak

Ogun State mulls relocation of communities over gas leak

by The Editor
October 23 2026
0

...

Plugin Install : Widget Tab Post needs JNews - View Counter to be installed
  • Trending
  • Comments
  • Latest
2027: Tinubu repackages 2023 campaign promises in new manifesto

2027: Tinubu repackages 2023 campaign promises in new manifesto

November 12 2026
Katsina mob kills Customs officer for shooting passenger

Hisbah bans girls’ night hawking in Katsina

November 12 2026
Flamingos: All hail world champions! – Punch

Flamingos: All hail world champions! – Punch

November 12 2026
Canada flags Nigeria, 16 African countries as high-risk in new travel advisory

Canada to fast-track permanent residence for 200,000 foreigners in 2027

November 12 2026

EDITORIAL REVIEW

Flamingos: All hail world champions! – Punch

Flamingos: All hail world champions! – Punch

by The Editor
November 12 2026
0

FG outlines criteria for N50k cash grant beneficiaries

Tinubu’s N50,000 relief for the vulnerable – Punch

by The Editor
November 11 2026
0

There are drug addicts, vagabonds among traditional rulers, says Obasanjo

13% derivation: Fiscal federalism to the rescue – Punch

by The Editor
November 10 2026
0

Nigeria’s damning food affordability crisis – Punch

Nigeria’s damning food affordability crisis – Punch

by The Editor
November 2 2026
0

Four states hold high-level talks to tackle insecurity

Boko Haram compounding Nigeria’s case – Punch

by The Editor
October 23 2026
0

Opinion

NAFDAC mops up Europharm products nationwide

What is a Nigerian’s life worth?

by The Editor
November 2 2026
0

...

Blackouts: Broken promises, powering failure – Punch

The revenge of Band A

by The Editor
October 27 2026
0

...

2027: Wike, APC governors clash over Rainbow Coalition

Why are governors getting worse?

by The Editor
October 13 2026
0

...

As we celebrate the girl-child, let us not forget the boy-child

As we celebrate the girl-child, let us not forget the boy-child

by The Editor
October 12 2026
0

...

Plugin Install : Popular Post Widget need JNews - View Counter to be installed
  • Home
  • Headlines
  • Latest News
  • Governance
  • Business
  • Financial Crimes
  • Opinion
  • Editorials

© 2026 TheCitizen Ng. All Rights Reserved.

No Result
View All Result
  • Home
  • Headlines
  • Latest News
  • Governance
  • Business
  • Financial Crimes
  • Opinion
  • Editorials

© 2026 TheCitizen Ng. All Rights Reserved.